For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Income tax benefit | - | 0* | - | - |
| License revenue | 300 | - | - | - |
| General and administrative | 2,072 | -3,021* | 1,889 | 11,179 |
| Research and development | 355 | 1,848* | 2,551 | 1,953 |
| In-process research and development impairment | - | 0* | - | - |
| Total operating costs and expenses | 2,427 | -1,173 | 4,440 | 13,132 |
| Gain from operations | -2,127 | 1,173* | -4,440 | -13,132 |
| Foreign currency exchange (gain) loss | 1 | -26* | 14 | 20 |
| Interest income | 82 | 109* | 65 | 54 |
| Total other income | 83 | 83* | 79 | 74 |
| Net gain before income taxes | -2,044 | 1,255* | -4,361 | -13,058 |
| Profit Loss | - | 1,255* | - | - |
| Deemed Dividend From Warrant Inducement | - | 375* | - | - |
| Net gain attributable to common stockholders | -2,044 | 880 | -4,361 | -13,058 |
| Basic EPS | -0.05 | 0.044 | -0.45 | -1.93 |
| Diluted EPS | -0.05 | 0.044 | -0.45 | -1.93 |
| Basic Average Shares | 41,072,725 | 19,992,617 | 9,676,521 | 6,752,953 |
| Diluted Average Shares | 41,072,725 | 19,992,617 | 9,676,521 | 6,752,953 |
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)